Rheumatoid Arthritis

Logo of frontimmu

Link to Publisher's site
. 2019; 10: 266.
Published online 2019 Mar 4. doi: 10.3389/fimmu.2019.00266
PMCID: PMC6409305
PMID: 30886614

Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis

1Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, United States
2Wake Forest Center for Integrative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, United States
3Department of Rheumatology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC, United States
Edited by: Guido Moll, Charité Medical University of Berlin, Germany
Reviewed by: Jérôme Avouac, Université Paris Descartes, France; Rita Consolini, University of Pisa, Italy
*Correspondence: Christina L. Ross ude.htlaehekaw@ssorrhc
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
Received 2018 Aug 27; Accepted 2019 Jan 31.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of synovium (synovitis), with inflammatory/immune cells and resident fibroblast-like synoviocytes (FLS) acting as major players in the pathogenesis of this disease. The resulting inflammatory response poses considerable risks as loss of bone and cartilage progresses, destroying the joint surface, causing joint damage, joint failure, articular dysfunction, and pre-mature death if left untreated. At the cellular level, early changes in RA synovium include inflammatory cell infiltration, synovial hyperplasia, and stimulation of angiogenesis to the site of injury. Different angiogenic factors promote this disease, making the role of anti-angiogenic therapy a focus of RA treatment. To control angiogenesis, mesenchymal stromal cells/pericytes (MSCs) in synovial tissue play a vital role in tissue repair. While recent evidence reports that MSCs found in joint tissues can differentiate to repair damaged tissue, this repair function can be repressed by the inflammatory milieu. Extremely-low frequency pulsed electromagnetic field (PEMF), a biophysical form of stimulation, has an anti-inflammatory effect by causing differentiation of MSCs. PEMF has also been reported to increase the functional activity of MSCs to improve differentiation to chondrocytes and osteocytes. Moreover, PEMF has been demonstrated to accelerate cell differentiation, increase deposition of collagen, and potentially return vascular dysfunction back to homeostasis. The aim of this report is to review the effects of PEMF on MSC modulation of cytokines, growth factors, and angiogenesis, and describe its effect on MSC regeneration of synovial tissue to further understand its potential role in the treatment of RA.

Keywords: pulsed electromagnetic field (PEMF), rheumatoid arthritis (RA), mesenchymal stromal

Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting over 1.3 million Americans, and as much as 1% of the population worldwide (). Although RA predominantly affects large and small joints, it can affect other organs in the body, including those of the cardiovascular, pulmonary, and ophthalmologic systems (). The pathophysiology of RA includes abnormal activation of blood cells, namely macrophages, T-cells, and B-cells, which produce pro-inflammatory mediators (e.g., cytokines and growth factors) that initiate an inflammatory cascade that leads to joint damage (i.e., bone erosions) and systemic complications (). Current treatments include corticosteroids, traditional disease-modifying anti-rheumatic drugs (DMARDs), and anti-cytokines (biologics); however, these drugs have adverse effects which can be severe, including osteoporosis, alterations of metabolism, infection, bone marrow suppression, hepatitis, and an increased risk of malignancies (). As the disease progresses, joints are damaged resulting in impaired range of motion, joint deformity, and dysfunction (). Although the currently approved drugs are known to prevent further joint damage, the effect of these drugs in repairing bone erosions has yet to be demonstrated, and pro-anabolic agents are needed to promote bone formation at the erosion sites (). Therefore, innovative and safe strategies aimed at both reducing inflammation and promoting tissue regeneration are urgently needed to inhibit the progression of RA.

A promising novel strategy for the treatment of RA is the local or systemic delivery of extremely low frequency pulsed electromagnetic fields (PEMF) to target mesenchymal stromal cells/pericytes (MSCs) to improve their ability to modulate immune responses and repair tissue. PEMF are physical stimuli that affect biological systems through the production of coherent or interfering fields that modify fundamental electromagnetic frequencies generated by living organisms (). PEMF activate multiple intracellular pathways, including numerous processes and biochemical mechanisms within both the immune and microvascular systems. There are two methods in which PEMF can be applied to biological tissues: capacitive or inductive coupling. In direct capacitive coupling, an electrode must be placed on the tissue (); however, in non-direct capacitive coupling/inductive coupling, electrodes do not have to be in direct contact with the tissue because the electric field produces a magnetic field that, in turn, produces a current in the conductive tissues of the body (). PEMF therapy is based on Faraday’s law, a basic law of electromagnetism that predicts how a magnetic field will interact with an electric circuit to produce an electromotive force known as electromagnetic induction. This law dictates the more charge that is needed, the higher the intensity of the PEMF signal needs to be. This is represented by the equation dB/dT, where B is peak magnetic intensity, T is time, and d is the derivative (or change) in these units. Since the PEMF signal needs to be able to pass deep enough through the tissue to produce healing results, field intensity, frequency, and time of exposure are all important components in the dosimetry. PEMF follows the inverse square law, so it drops off exponentially from the distance of the surface of the coil; therefore, the closest tissue to the coil (applicator) gets the maximum intensity, and furthest tissue from the coil gets the least intensity.

PEMF can alter cell function by triggering the forced vibration of free ions on the surface of the plasma membrane, causing external oscillating field disruptions in the electrochemical balance of transmembrane proteins (ion channels) (). It has been suggested that PEMF may be propagated and effectively amplified along the entire signal transduction pathway, thereby modifying cell behavior (). Indeed, several studies have reported that PEMF can modulate both cell surface receptor expression/activation, and downstream signal transduction pathways, thereby restoring homeostatic cell functions such as viability, proliferation, differentiation, communication with neighboring cells, and interaction with components of the extracellular matrix (ECM) ().

By modulating the expression of various signaling cascades and cellular information processing networks to potentially restore them to homeostatic (healthy) production levels, PEMF is showing promise as a treatment for autoimmune diseases such as RA (). Changes in the cells’ microenvironment are integrated into a survival response by complex signal transduction mechanisms (). Lipid nanopores forming stable, ion channel conduction pathways in the plasma membrane of cells (), explain the conduction of ions into the cell from the extracellular space, specifically calcium (Ca2+) ion flux (). It has been postulated that a direct effect of PEMF on phospholipids within the plasma membrane stimulates the production of second messengers, initiating multiple intracellular signal transduction pathways ().

PEMF intensity is dependent upon wave amplitude/field strength measured in units of Tesla (T), or Gauss (10,000 T). In order to deliver a therapeutic PEMF, it is necessary to optimize three important parameters: frequency, intensity, and duration/time of exposure (). Previous studies have conclusively shown that optimization of the frequency, intensity, and time of exposure is helpful in attaining consistent beneficial results in experimental arthritis in rats (). A 5 Hz frequency, 4 microT (?T) intensity, applied for 90 min to the rat paw was reported to be the optimal dosimetry for lowering edema, and reducing swelling, inflammatory cell infiltration, hyperplasia, and hypertrophy of cells lining the synovial membrane (). Preliminary studies in humans have also reported that PEMF can reduce chronic joint swelling and pain in patients with RA (). Further, the beneficial effects of PEMF have been reported to last up to 3 months or longer in human patients with chronic inflammatory/autoimmune disorders () with no evidence of adverse effects ().

PEMF Modulates RA Tissue Pathogenesis via Modulation of MSCs and FLS

Normal synovium composition consists of a well-organized matrix of fibroblast-like cells (FLS) and macrophage-like cells known as synovial cells or synoviocytes. The joint-lining synovial membrane consists of a layer of macrophage-like (type a) synoviocytes, fibroblast-like synoviocytes (FLS–type b), and mesenchymal stromal cells (MSCs) (). In RA, the synovium becomes infiltrated by cells of lympho-hematopoietic origin, namely T-helper cells, B cells, and macrophages, which cause synovial hyperplasia and neoangiogenesis (). The resulting inflammatory response poses considerable risks for joint damage, and articular dysfunction if left untreated (). Type A synoviocytes are CD163+, CD68+, CD14+/lo cells that localize to the intima and the subintimal layers of the synovial membrane and proliferate in response to inflammatory conditions. Under pathological conditions, Type A (macrophage-like) synoviocytes contribute to cartilage destruction by producing pro-inflammatory cytokines. They originate in the bone marrow, like other mononuclear phagocytes, and are constantly replaced via the circulation. In rheumatoid synovium sections, 80–100% of the synovial lining cells are macrophage-like cells functioning as antigen processing- and antigen-presenting cells to T lymphocytes (). Type A synoviocytes also induce the formation of osteophytes through the release of transforming growth factor-beta (TGF-?) 3 and bone morphogenetic proteins (BMP)-2 and BMP-4 ().

FLS, a heterogeneous population of fibroblastic cells, express CD55 and also play a central role in the maintenance of joint inflammation and the destruction of cartilage (). RA joint pathology is characterized by chronic inflammation of the synovium (synovitis), which causes cartilage and bone erosion between inflammatory/immune cells and resident FLSs (). Under healthy conditions, these cells contribute to the homeostasis of normal joints by synthesizing extracellular matrix (ECM) molecules and secreting specific components of synovial fluid (). Synovial Fibroblasts respond to inflammatory cytokines, mainly TNF-?, by producing a large variety of inflammatory mediators along with tissue destruction ().

MSCs are also shown to be present in various areas of the joint (). Immunoregulatory function of MSCs can be modulated by proinflammatory cytokines such as IFN-?, TNF-?, and IL-1? or ? (). Synovial MSCs express CD44, CD90, CD271, and UDPGD, required for hyaluronan synthesis, and possess high chondrogenic potential (). Synovial MSCs, which when healthy, maintain tissues and facilitate the repair process. While both FLSs and MSCs are part of the synovium, their functional specialization and diversification may be dependent on their positional information and environmental cues (); however the relationship between MSCs and FLSs remains unclear. MSCs in the synovial lining could be perhaps stem cells interspersed between the FLSs and synovial macrophages. Alternatively, the FLSs could be a stage of differentiation of the MSC lineage, taking on FLS-specific properties, but still maintaining their MSC lineage ().

While immune cells have been extensively investigated in the pathogenesis of RA, little is known about the in vivo functions of FLSs/MSCs in the regulation of immune homeostasis in physiology and their contribution to immune regulation in RA. Under normal conditions, FLSs/MSCs would control the degree of immune responses; however, the inflammatory environmental signals cue inflammatory cells, unsettling the immunomodulatory functions of FLSs/MSCs, damaging the pannus, contributing to chronic disease maintenance and progression (). Aberrant cross-talk between FLSs/MSCs and immune cells (T-cells, B cells and macrophages) could be a vicious cycle of chronic RA progression (). This could be due to MSCs ability to express inflammatory mediators such as prostaglandin E2 and IL-6. Also enzymatic production of arachidonic acid enhanced in MSCs by TNF-? or IFN-? have a deleterious effect on immune cells in the RA microenvironment (). Thus, heterogeneity of MSCs in terms of immune and hematopoietic function can either maintain immune homeostasis or promote RA pathogenesis.

Healthy MSC function has been shown to inhibit inflammatory responses and improve regeneration () by: (a) inhibiting inflammatory cell infiltration and inflammatory cytokine release (); (b) activating regulatory T-cells (Tregs) (); and (c) influencing the transition from Th1 cells toward Th2 cells (). MSCs exert their regulatory activities through the release of immunomodulatory molecules such as IL-10, TGF-?, PGE2, and indoleamine 2,3-dioxygenase (IDO) (). In addition, MSCs are able to polarize macrophage differentiation toward the anti-inflammatory M2 phenotype in vitro and in vivo (); inhibit T-cell proliferation (); and induce the formation of Tregs (). As such, MSCs are an attractive target for immunomodulation, particularly in the treatment of cartilage injuries and diseases such as RA (), as modulation of resident synovial MSCs could lead to the control of the inflammatory immune response () and ultimately decrease the RA-associated angiogenesis processes.

Stimulation of resident MSCs, or other tissue specific cells to improve inflammation and/or tissue regeneration, is a relatively new concept in medicine that could potentially be achieved by the use of PEMF (). PEMF has the potential to prevent aberrant and promote healthy MSC function. PEMF has been shown to induce differentiation of MSCs to promote immunomodulation and improve cartilage and bone regeneration in vitro () and in vivo (). Stimulation of chondrogenesis in situthrough PEMF could lead to an increase of cartilage matrix and collagen levels in RA damaged joints (). In addition, PEMF promotes proliferation of endogenous chondroblasts (), supports the enhancement of cartilage regeneration (), and potentiates MSCs’ anti-inflammatory responses. In RA, PEMF also upregulates adenosine receptors to increase anti-inflammatory effects on both chondrocytes and FLS and reduces levels of enzymes produced by FLS and osteoclasts that lead to bone destruction () (Table 1).

Table 1

Frequency Specific Effects of PEMF on cells and tissues associated with RA.

Authors Frequency (Hz) Field strength (mT) Time of exposure Outcome
Chen et al. () 15 2 8 h/day Increased cartilaginous matrix deposition and enhanced chondrogenic gene expression in SOX-9, COL II, and aggrecan in MSCs
De Mattei et al. () 75 2.3 At 1, 6, 9, and 18 h for 3 and 6 days Increased proliferation of human articular chondrocytes
Esposito et al. () 75 1.8 or 3 8 h/day for up to 21 days Increased cell division, cell densities, COL II, and chondrogenesis in MSCs
Fitzsimmons () 15 1 A single 30 min exposure Prevented increases in NO, cGMP, and increased DNA content in proliferation rates of chondrocytes
Meyer-Wagner et al. () 15 5 45 min every 8 h, 3x/day for 21 days Increased GAG/DNA and improved chondrogenic differentiation via COL II in BM-MSCs
Parate et al. () 15 2 1 application for 10 min Increased Sox-9, COL II, and aggrecan. Stimulated chondrogenesis via calcium homeostasis in MSCs
Varani et al. () 75 1.5 Continuously for 1 week Upregulated A2A and A3 ARs increasing anti-inflammatory properties in both chondrocytes and FLS

PEMF, pulsed electromagnetic field; Hz, Hertz; mT, milliTesla; h, hour; d, day; NO, nitric oxide; BM-MSCs, bone marrow mesenchymal stromal cells; GAG, glycosaminoglycans; cGMP, cyclic guanosine monophosphate; COL, collagen; AR, adenosine receptor; FLS, fibroblast-like synoviocytes.

PEMF as an Alternative to Biologics in the Treatment of RA

The cytokine network in RA is complex and involves an interplay of both pro-inflammatory and anti-inflammatory cytokines. Regulating this cellular microenvironment is essential to maintaining healthy MSC phenotype. In RA, the macrophage-mediated inflammatory response is the main source of proinflammatory cytokines, including TNF-?, IL-1?, IL-6, C-X-C motif chemokine ligand 4 (CXCL4), and CXCL7 (). While data from clinical trials show some efficacy using biologic drugs, the blockade of these cytokines does not fully control RA in all patients (). Interleukin-4 (IL-4) and?10 (IL-10) are pleiotropic cytokines considered to be promising modulators to control RA, as these regulatory mediators may have a direct inhibitory effect on the macrophage activity in the synovium (). While the targeted suppression of key inflammatory pathways involved in joint inflammation and destruction allows better disease control, it comes at the price of elevated infection risk, since blockade of these pathways can lead to broad immunosuppression (). In addition, these drugs are expensive, costing around $1,000–$3000 US per month, and the risks of prolonged treatment remain uncertain (). While biologic drugs for RA work by halting the progression of joint damage, and sometimes pushing RA into remission, preliminary evidence shows loss of efficacy over time; therefore, rotation between available biological drugs is often necessary to maintain a good clinical response (). Another unknown is the appropriate treatment duration for biologic medications. Once remission of the disease is achieved, it is unclear whether the drugs need to be maintained, or if they can safely be suspended ().

The pro-inflammatory transcription factor nuclear factor kappa B (NF-kB) plays crucial roles in the regulation of inflammation and immune responses by controlling the transcription of multiple cytokine genes (e.g., TNF-?, IL-1, IL-6, and INF-?), as well as genes involved in cell survival. Given its central role in the control of inflammation and immunity, it is not surprising that inappropriate NF-kB activity has been linked to many autoimmune and inflammatory diseases, including RA (). Exposure to PEMF induces early upregulation of adenosine receptors A2A and A3 that reduce PGE2 and pro-inflammatory cytokines such as TNF-?, which combine to inhibit the activation of transcription factor NF-kB (). Specifically, at 5 Hz, 0.04 mT, a 1 h exposure to PEMF has been shown to down-regulate both NF-kB and TNF-? in murine macrophages (). By inhibiting NF-kB activation (), exposure to PEMF led to decreased production of TNF-?, IL-1?, IL-6, and PGE2 in human chondrocytes, osteoblasts, and synovial fibroblasts ().

It is important to note inflammatory cytokines can prevent MSCs differentiation, repressing their stem cell function. Cytokines, ions, growth factors, and chemokines modulate physiological processes of MSCs through their microenvironment (). In both animal and clinical trials, TNF-?, IL-1?, IL-6, PGE2, and the anti-inflammatory cytokine IL-10 have all been shown to be modulated by PEMF (). Exposure to PEMF has also been shown to stabilize plasma membrane Ca2+ ATPase (PMCA) activity (). PMCA is a transport protein that removes Ca2+ from the cell, and thereby regulates the intracellular concentration of Ca2+ in all eukaryotic cells (). These extremely low frequencies have a documented record of long-term safety, and their anti-inflammatory properties are well-established in animal arthritis models (). In double-blind clinical trials in which the knees and spine of RA patients were exposed to 5 Hz, 10–20 Gauss PEMF exposure for 10–30 min/day, 3–5x/ week for 1 month, up to a 47% improvement was documented in various clinical measures such as pain severity, joint tenderness and range of motion (). These beneficial clinical effects were attributed to PEMF’s ability to significantly reduce the production of the RA-associated inflammatory cytokines IL-1?, IL-6, TNF-?, and PGE2, while increasing the levels of the anti-inflammatory cytokine IL-10 in peripheral blood mononuclear cells (PBMCs) such as T-cells and macrophages ().

Table 2 provides a summary of the various parameters with which PEMF has been explored to-date for its ability to modulate cytokines and growth factors.

Table 2

Frequency Specific Effects of PEMF on cytokines and growth factors associated with RA.

Authors Frequency (Hz) Field strength (mT) Time of exposure Outcomes (in vitro?)
Gomez-Ochoa et al. () 50/60 15 15 min/day/days 7, 8, 9 Significantly decreased IL-1? and TNF-?, while increasing IL-10 in human fibroblasts
Ongaro et al. () 75 1.5 24 h Inhibited release of PGE2, and IL-1? and IL-6 production, while stimulating release of IL-10 in synovial fibroblasts
Ross and Harrison () 5.1 0.04 1 h Inhibited production of TNF-? and NF-kB in macrophages
Tang et al. () 15 1 6 h Significantly decreased production of IL-1? and IL-6 in vertebral joint cells
Vincenzi et al. () 75 1.5 24 h Inhibited NF-kB activation, and decreased the production of IL-6 and PGE2 in chondrocytes

PEMF, pulsed electromagnetic field; Hz, Hertz; mT, milliTesla; h, hour; TNF-?, tumor necrosis factor alpha; IL, interleukin; PGE2, prostaglandin E2; VEGF, vascular endothelial growth factor; NF-kB, nuclear factor kappa B.

Ability of ELF-PEMF to Potentially Restore Angiogenic Homeostasis

Angiogenesis is the formation of new capillaries from pre-existing vasculature, and this process plays a critical role in the pathogenesis of several inflammatory autoimmune diseases such as RA (). In RA, excessive infiltration of circulating leukocytes into the inflamed joint induces synovial tissue macrophages and fibroblasts to produce inflammatory and proangiogenic factors, such as TNF-?, IL-1?, IL-6, IL-17, and TGF-? that trigger neoangiogenesis (). This inappropriate neoangiogenesis is also known to play a key role in the abnormal tissue growth, disordered tissue perfusion, abnormal ossification, enhanced responses to normal or pathological stimuli (), and the development of the hyperplasic proliferative pathologic synovium (). This area, called “pannus,” destroys articular cartilage, subchondral bone, and periarticular soft tissue, further increasing the density of synovial blood vessels required to develop the hyperplasic and invasive nature of the RA synovium (). Although these newly formed blood vessels deliver oxygen to the augmented inflammatory cell mass, the neovascular network is dysfunctional and thus fails to restore tissue oxygen homeostasis. As a result, the rheumatoid joint remains in a markedly hypoxic environment (). Hypoxia has been shown to activate NF-kB, which in turn activates macrophages, fibroblasts, and endothelial cells (), stimulating further release of proinflammatory cytokines and growth factors () that directly or indirectly mediate inflammatory angiogenesis (). Repetitive cycles of hypoxia and reoxygenation, together with oxidants produced by phagocytic cells, promote a state of chronic oxidative stress within the microenvironment of the affected joint, leading to the generation of reactive oxygen species (ROS), which can further contribute to tissue damage. Given the central role neoangiogenesis plays in the pathogenesis of RA, anti-angiogenic therapy appears ideal.

While angiogenesis forms from new capillaries from pre-existing vessels, vasculogenesis is established capillarity formation from endothelial precursor cells (EPCs). Current understanding of the role of angiogensis and vasculogensis in RA is a focus of therapeutic intervention (). Angiogenesis is profuse in RA and causes defective EPC function, leading to atherosclerosis and vascular disease in arthritis (). Angiogenesis is essential for the expansion of synovial tissue in RA: pre-existing vessels facilitate the entry of blood-derived leukocytes into the synovial sublining, to generate and potentiate inflammation. Several steps are involved in angiogenesis, each of which is modulated by specific factors (). The process starts with growth factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) binding to their cognate receptors on endothelial cells (ECs) and activation of these cells to produce proteolytic enzymes (). Recent evidence has emerged that implicates VEGF to be one of the key players in RA pathogenesis and vascular abnormalities (). For example, VEGF expression levels in synovial fluid and tissues have been shown to correlate with the clinical severity of RA, and with the degree of joint destruction (). Proangiogenic factors such as VEGF are modulators of change in vascular permeability, and studies suggest that capillaries are more deeply distributed in the RA synovium, compared with normal tissue (). The synthesis of VEGF is induced by cytokines and growth factors (e.g., TNF-?), and through oxidative stress, and hypoxia (). Overexpression of VEGF-C in FLS by stimulation with TNF-alpha may play an important role in the progression of synovial inflammation and hyperplasia in RA by contributing to local lymphangiogenesis and angiogenesis (). Both oxidative stress and hypoxia are present within the joints of RA patients (). TNF-? has also been reported to induce the release of VEGF from endothelial cells (), which can lead to an imbalance between endothelial cells (EC) tube formation and the parallel development of MSCs/pericytes and thereby altering angiogenesis and vasculogenesis ().

MSCs are perivascular cells that are precursors of pericytes and adventitial cells that envelop microvessels and surround larger arteries and veins, as well as the myriad of other stromal cells that act in concert to maintain/restore tissue homeostasis (). Aberrant MSCs can release various inflammatory cytokines and VEGF (), enhancing tissue inflammation (), and promoting angiogenesis, both of which are of direct relevance to the pathogenesis of RA (). Pericytes have been shown to possess stem-like qualities, and have been hypothesized to be the in vivo counterparts, or precursors, of MSCs (). MSC/pericytes are recognized for their central role in blood vessel formation, and they act as a repair system in response to injury by maintaining the structural integrity of blood vessels (). Pericytes have been shown to both stabilize and promote capillary sprouting (). Perivascular pericytes envelop the vascular tube surface of the inner EC layer that lines the blood vessel wall (). Because of their close anatomical and functional association with ECs, pericytes are thought to regulate capillary diameter and physically influence EC behavior () via contraction in response to electrical or neurotransmitter stimulation (). Homing of endothelial progenitor cells (EPCs) to an RA injury site is important for repair of vasculature and angiogenesis. Applied direct current (DC) electric fields has been reported to guide EPC migration through VEGF receptor signaling in vitro, controlling EPC behavior to heal injury sites in the vascular (). PEMF has also been reported to increase the number and function of circulating EPCs in treating myocardial ischemia/reperfusion (I/R) injury in rats ().

Collectively, these data point to EPCs and MSCs as highly localized modulators of blood flow (). It has also been found that MSCs can stabilize blood vessels and contribute to tissue and immune system homeostasis under physiological conditions by assuming a more active role in tissue repair in response to injury (). As such, MSCs/pericytes represent a logical target for new in vivo therapeutic approaches to treating the vascular abnormalities present in RA and halting disease progression to restore homeostasis (). Since PEMF have been shown to stimulate the production of MSCs (), and MSCs can stabilize blood vessels and contribute to immune system homeostasis, the possibility exists that PEMF could provide a therapeutic application to restore immune balance and bringing hypoxic conditions and synovial angiogenesis back to a state of homeostasis.

MSCs represent an ideal target on which PEMF can initiate their effects on the aberrant immune response that drives the pathogenesis of RA. MSCs/pericytes down-modulate the production of synovial macrophages, which trigger production of cytokines, such as IL-4, that initiate the proliferation of synovial fibroblasts, promoting the expression of growth factors such as VEGF and TGF-? (). Exposure of MSCs/pericytes to PEMF appears to trigger a cascade of downstream effects on multiple pathways, affecting macrophages, T-cells, and B cells, and the cytokines that are produced. The cumulative result of these varied effects is modulation of VEGF and TGF-?, which ultimately curtails the production of synovial fibroblasts and osteoclasts and halts bone resorption, while promoting the production of chondrocytes and osteoblasts to restore cartilage and bone health/integrity (Figure 1).

An external file that holds a picture, illustration, etc.
Object name is fimmu-10-00266-g0001.jpg

PEMF are physical stimuli that produce membrane activations of multiple cellular pathways. (A) RA pathogenesis begins with activation of immune function increasing proinflammatory cytokines and upregulating growth factors to increase FLS proliferation and bone resorption. (B) Application of PEMF could potentially bring immune function back to homeostasis.

The effects of PEMF on vessel growth and development, both in vitro and in vivo, support the use of this approach to therapeutically modulate the aberrant angiogenesis present in RA, (). PEMF has been reported to improve osteochondral ossification, and modulate nociception () through the down-regulation of neovascularization () in both animals and humans with RA (). It has also been reported to significantly reduce activation levels of VEGF (), to inhibit the proliferative ability of human umbilical vein endothelial cells (HUVECs) (), and to reduce the extent of vascularization in diseased tissue (). Approximately half of the cited studies of PEMF application indicate a vasodilatory effect, the magnitude of which is dependent upon the initial vessel tone. The remaining half indicates that PEMF has the potential to trigger vasoconstriction. The ultimate outcome of PEMF application thus appears to depend on the cellular/mechanistic basis of the disease in question (). A summary of some of the studies that have explored the use of various regimens of PEMF to potentially restore angiogenic homeostasis appear in Table 3.

Table 3

Frequency Specific Effects of PEMF on angiogenesis-associated RA.

Authors Frequency (Hz) Field strength (mT) Time of exposure Outcome
Delle-Monache et al. () 50 2 1, 6, and 12 h Significantly reduced the expression and activation levels of VEGF in HUVECs
Leoci et al. () 8 1.05 5 min/2x/day for 3 weeks Reduction in peak gradient blood flow in prostatic hyperplasia
Okana et al. () Static 120 24/7 for 10 days Significantly promoted tubular formation in area density and length of tubules and improved gradient force on vessels
Vincenzi et al. () 75 1.5 24 h Inhibited VEGF activation in chondrocytes
Wang et al. () Static 2–4 24 h Significantly inhibited the proliferation ability of HUVECs to treat pathological angiogenesis

PEMF, pulsed electromagnetic field; Hz, Hertz; mT, milliTesla; HUVEC, human umbilical vein endothelial cell; VEGF, vascular endothelial growth factor; ECs, endothelial cells.

Conclusion

Under normal physiological conditions, MSCs in the joint are believed to contribute to the maintenance and repair of joint tissues. In RA, however, the repair function of MSCs appears to be repressed by the inflammatory milieu. In addition to being passive targets, MSCs could interact with the immune system and play an active role in the perpetuation of arthritis and progression of joint damage (). Achieving homeostasis in the face of acute inflammatory/immune challenges in the human body involves maintaining a balance of highly complex biochemical and cellular interactions. When this delicate balance is upset, acute inflammatory and immune responses designed to quickly eliminate a transient threat become chronic, and inflammatory/autoimmune disease sets in. RA is a paradigmatic autoimmune disease, and current RA therapies target inflammatory molecules involved in autoimmune activation. Despite the therapeutic improvements in RA, there are still a substantial number of patients who respond only transiently to these approaches, and others who do not respond at all. As such, there is an urgent unmet need to identify complementary and innovative therapies for the treatment of RA.

PEMF is emerging as a novel and highly promising means of treating chronic inflammation and aberrant immunity that exists in diseases such as RA. It can be used to target aberrant MSCs to potentially bring the inflammatory milieu back to homeostasis. Cellular electrical properties such as membrane surface charge and membrane potential can be readily influenced by PEMF (), which can affect oscillatory frequencies of the myriad of enzymes present within the cells. PEMF can also influence cell membranes, nucleic acids, and bioelectrical phenomena generated by coherent groups of cells that are essential to cell-to-cell communication processes (). PEMF appears to exert its effects on cellular function and differentiation by altering the spatial and temporal patterns of intracellular calcium (Ca2+) concentration () and restoring levels/activity of potassium (K+) channels (). By restoring normal Ca2+ ion flux and Na+/K+ balance, the cell can begin the process of down-regulating inflammatory cytokines, heat-shock proteins, and proangiogenic molecules such as VEGF (), making it possible for the body to commence rebuilding healthy cartilage. Using PEMF to modulate inflammation and immune function is relatively safe in contrast to the broad immunosuppression currently in clinical favor (). An alternative to immunosuppression–healthy immunomodulation and tissue repair–can be achieved by targeting MSCs with PEMF. While traditional approaches target individual molecules or signaling pathways, PEMF works on all cellular/organismal systems in a holistic and integrative manner by potentially bringing the transmission and flow of information (signal transduction) back to a state of homeostasis via coherence of sinusoidal pulses (). There are other potential advantages of PEMF including low-cost, easy-to-use at-home, without adverse effects. While cell therapies or biologics suffer from the possibility of loss of efficacy over time (), preliminary clinical studies with PEMF have shown no loss of efficacy even after exposure to the field has ended (). Another key unsolved problem in the treatment/management of RA is determining the optimal duration of therapy, and the lack of data to inform clinicians whether drugs should be suspended once remission of the disease is obtained (). PEMF has the advantage of use without concerns regarding global immunosuppression until the desired clinical outcome is obtained (). Since MSCs are ubiquitous, targeting their regenerative, and anti-inflammatory capacities would be an optimal combination of exogenous (PEMF), and endogenous (MSC) therapies. Clinical applications include whole-body mats for systemic approach (), and hand-held devices for localized therapy (). For localized applications, direct capacitive coupling mechanisms such as electrodes adhere to the site of inflammation/tissue degeneration. For non-direct capacitive/inductive coupling, mats can be used for full body applications. Current research shows optimal frequency < 75 Hz, with optimal intensity (field strength) < 5 mT, and optimal time courses ranging between 15 and 90 min, with longer duration most effective for severe symptoms.

Author Contributions

GA-P provided expertise and contributed editorial and written content on mesenchymal stromal cells (MSCs). DA provided expertise on RA and contributed editorial and written content on RA pathology. CR wrote the manuscript and provided expertise on the therapeutic effects of pulsed electromagnetic field for the treatment of RA.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

We wish to acknowledge the Guth Family Fund WFBHA-63313-740-120330-740196 for their continued support.

References

1. Network RAS. Rheumatoid Arthritis Facts and Statistics. (2016) Available online at: https://www.rheumatoidarthritis.org/ra/facts-and-statistics/ (Accessed August 31, 2017).
2. Isaacs J. The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol.(2010) 10:605–11. 10.1038/nri2804 [PubMed] [CrossRef[]
3. Smolen J, Aletaha D, Redlich K. The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nat Rev Rheumatol. (2012) 8:235–43. 10.1038/nrrheum.2012.23 [PubMed] [CrossRef[]
4. Center JHA. Rheumatoid Arthritis Treatment. (2017) Available online at: https://www.hopkinsarthritis.org/arthritis-info/rheumatoid-arthritis/ra-treatment/ (Accessed September 11, 2017).
5. Ethgen O, de Lemos Esteves F, Bruyere O, Reginster JY. What do we know about the safety of corticosteroids in rheumatoid arthritis? Curr Med Res Opin. (2013) 29:1147–60. 10.1185/03007995.2013.818531 [PubMed] [CrossRef[]
6. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. . Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritisAnn Rheum Dis. (2014) 73:529–35. 10.1136/annrheumdis-2013-204575 [PubMed] [CrossRef[]
7. Paleolog E. The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Path. (2009) 90:249–61. 10.1111/j.1365-2613.2009.00640.x [PMC free article] [PubMed] [CrossRef[]
8. Fu H, Hu D, Zhang L, Tang P. Role of extracellular vesicles in rheumatoid arthritisMol Immunol.(2018) 93:125–32. 10.1016/j.molimm.2017.11.016 [PubMed] [CrossRef[]
9. Ganesan K, Gengadharan A, Balachandran C, Manohar B. Low frequency pulsed electromagnetic field – a viable alternative for arthritisIndian J Exp Biol. (2009) 47:939–48. 10.1002/bem.20535 [PubMed] [CrossRef[]
10. Ross C, Siriwardane ML, Almeida-Porada G, Proada CD, Brink P, Christ GJ, et al. The effect of low-frequency electromagnetic field on human bone-marrow derived mesenchymal stem/progenitor cell differentiationStem Cell Res. (2015) 15:96–108. 10.1016/j.scr.2015.04.009 [PMC free article] [PubMed] [CrossRef[]
11. Trock D. Electromagnetic fields and magnets: investigational treatment for musculoskeletal disordersRheum Dis Clin North Am. (2000) 26:51–62. 10.1016/S0889-857X(05)70119-8 [PubMed] [CrossRef[]
12. Stiller M, Pak GH, Shupack JL, Thaler S, Kenny C, Jondreau L. A portable pulsed electromagnetic field (PEMF) device to enhance healing of recalcitrant venous ulcers: a double-blind, placebo-controlled clinical trialBr J Dermatol. (1992) 127:47–54. 10.1111/j.1365-2133.1992.tb08047.x [PubMed] [CrossRef[]
13. Cohen D, Palti Y, Cuffin BN, Schmid SJ. Magnetic fields produced by steady currents in the bodyProc Natl Acad Sci USA. (1980) 77:1447–51. [PMC free article] [PubMed[]
14. Liboff A, McLeod BR. Kinetics of channelized membrane ions in magnetic fieldBioelectromagnetics. (1988) 9:39–51. [PubMed[]
15. Delle-Monache S, Angelucci A, Sanità P, Iorio R, Bennato F, Mancini F, et al. . Inhibition of angiogenesis mediated by extremely low-frequency magnetic fields (ELF-MFs)PLoS ONE. (2013) 8:e79309. 10.1371/journal.pone.0079309 [PMC free article] [PubMed] [CrossRef[]
16. Gordon G. Designed electromagnetic pulsed therapy: clinical applicationsJ Cell Physiol. (2007) 212:579–82. 10.1002/jcp.21025 [PubMed] [CrossRef[]
17. Ross C. The use of electric, magnetic, and electromagnetic field for directed cell migration and adhesion in regenerative medicineBiotechnol Prog. (2016) 33:5–16. 10.1002/btpr.2371 [PubMed] [CrossRef[]
18. Chen C, Lin YS, Fu YC, Wang CK, Wu SC, Wang GJ, et al. . Electromagnetic fields enhance chondrogenesis of human adipose-derived stem cells in a chondrogenic microenvironment in vitroJ Appl Physiol. (2013) 114:647–55. 10.1152/japplphysiol.01216.2012 [PubMed] [CrossRef[]
19. Sun W, Gan Y, Fu Y, Lu D, Chiang H. An incoherent magnetic field inhibited EFG receptor clustering and phosphorylation induced by a 50 Hz magnetic field in cultured FL cellsCell Physiol Biochem.(2008) 33:508–14. 10.1159/000185524 [PubMed] [CrossRef[]
20. Nie K, Henderson A. MAP kinase activation in cells exposed to a 60 Hz electromagnetic fieldJ Cell Biochem. (2003) 90:1197–206. 10.1002/jcb.10704 [PubMed] [CrossRef[]
21. Goodman R, Lin-Ye A, Geddis MS, Wickramaratne PJ, Hodge SE, Pantazatos SP, et al. . Extremely low frequency electromagnetic fields activate the ERK cascade, increase hsp70 protein levels and promote regeneration in planariaInt J Radiat Biol. (2009) 85:851–9. 10.1080/09553000903072488 [PMC free article] [PubMed] [CrossRef[]
22. Bekhite M, Finkensieper A, Abou-Zaid FA, El-Shourbagy IK, Omar KM, Figulla HR, et al. . Static electromagnetic fields induce vasculogenesis and chondro-osteogenesis of mouse embryonic stem cells by reactive oxygen species-mediated up-regulation of vascular endothelial growth factorStem Cells Dev.(2010) 19:731–43. 10.1089/scd.2008.0266 [PubMed] [CrossRef[]
23. Li X, Zhang M, Bai L, Bai W, Xu W, Zhu H. Effects of 50 Hz pulsed electromagnetic fields on the growth and cell cycle arrest of mesenchymal stem cells: an in vitro studyElectromagn Biol Med. (2012) 31:356–64. 10.3109/15368378.2012.662194 [PubMed] [CrossRef[]
24. Ganguly K, Sarkar AK, Datta AK, Rakshit A. A study of the effects of pulsed electromagnetic field therapy with respect to serological grouping in rheumatoid arthritisJ Indian Med Assoc. (1998) 96:272–5. [PubMed[]
25. Shupak N, McKay JC, Nielson WR, Rollman GB, Prato FS, Thomas AW. Exposure to a specific pulsed low-frequency magnetic field: a double-blind placebo-controlled study of effects on pain ratings in rheumatoid arthritis and fibromyalgia patientsPain Res Manag. (2006) 11:85–90. 10.1155/2006/842162 [PMC free article] [PubMed] [CrossRef[]
26. Gómez-Ochoa I, Gómez-Ochoa P, Gómez-Casal F, Cativiela E, Larrad-Mur L. Pulsed electromagnetic fields decrease proinflammatory cytokine secretion (IL-1? and TNF-?) on human fibroblast-like cell cultureRheumatol Int. (2011) 31:1283–9. 10.1007/s00296-010-1488-0 [PubMed] [CrossRef[]
27. Gajewski M, Rzodkiewicz P, Ma?li?ski S, Wojtecka-?ukasik E. The role of physiological elements in future therapies of rheumatoid arthritis. III The role of the electromagnetic field in regulation of redox potential and life cycle of inflammatory cellsRheumatol Clin. (2015) 53:219–24. 10.5114/reum.2015.54000 [PMC free article] [PubMed] [CrossRef[]
28. Ladoux B, Mège RM. Mechanobiology of collective cell behavioursNat Rev Mol Cell Biol. (2017) 18:743–57. 10.1038/nrm.2017.98 [PubMed] [CrossRef[]
29. Pakhomov A, Bowman AM, Ibey BL, Andre FM, Pakhomova ON, Schoenbach KH. Lipid nanopores can form a stable, ion channel-like conduction pathway in cell membraneBiochem Biophys Res Commun. (2009) 385:181–6. 10.1016/j.bbrc.2009.05.035 [PMC free article] [PubMed] [CrossRef[]
30. Ross C, Harrison BS. The use of magnetic field for the reduction of inflammation: a review of the history and therapeutic resultsAltern Ther Health Med. (2013) 19:47–54. [PubMed[]
31. Panagopoulos D, Karabarbounis A, Margaritis LH. Mechanism for action of electromagnetic fields on cellsBiochem Biophys Res Commun. (2002) 298:95–102. 10.1016/S0006-291X(02)02393-8 [PubMed] [CrossRef[]
32. Semenov I, Xiao S, Pakhomov AG. Primary pathways of intracellular Ca(2+) mobilization by nanosecond pulsed electric fieldBiochim Biophys Acta (2013) 1828:981–9. 10.1016/j.bbamem.2012.11.032 [PMC free article] [PubMed] [CrossRef[]
33. Tolstykh G, Beier HT, Roth CC, Thompson GL, Payne JA, Kuipers MA, et al. . Activation of intracellular phosphoinositide signaling after a single 600 nanosecond electric pulseBioelectrochemistry(2013) 94:23–9. 10.1016/j.bioelechem.2013.05.002 [PubMed] [CrossRef[]
34. Pilla A, Fitzsimmons R, Muehsam D, Wu J, Rohde C, Casper D. Electromagnetic fields as first messenger in biological signaling: application to calmodulin-dependent signaling in tissue repairBiochim Biophys Acta. (2011) 1810:1236–45. 10.1016/j.bbagen.2011.10.001 [PubMed] [CrossRef[]
35. Selvam R, Ganesan K, Narayana Raju KV, Gangadharan AC, Manohar BM, Puvanakrishnan R. Low frequency and low intensity pulsed electromagnetic field exerts its antiinflammatory effect through restoration of plasma membrane calcium ATPase activityLife Sci. (2007) 80:2403–10. 10.1016/j.lfs.2007.03.019 [PubMed] [CrossRef[]
36. Poornapriya T, Meera R, Devadas S, Puvanakrishnan R. Preliminary studies on the effect of electromagnetic field in adjuvant induced arthritis in ratsMed Sci Res. (1998) 26:467–9. []
37. Kumar V, Kumar DA, Kalaivani K, Gangadharan AC, Narayana Raju KVS, Thejomoorthy P, et al. . Optimization of pulsed electromagnetic field therapy for management of arthritis in ratsBioelectromagnetics. (2005) 26:431–9. 10.1002/bem.20100 [PubMed] [CrossRef[]
38. Sanseverino E, Vannini A, Castellacci P. Therapeutic effects of pulsed magnetic fields on joint diseasesPanminerva Med. (1992) 34:187–96. [PubMed[]
39. Ohtani S, Ushiyama A, Maeda A, Ogasawara Y, Wang J, Kunugita N, et al. The effects of ratio-frequency electromagnetic fields on T cell function during developmentJ Rad Res. (2015) 56:467–74. 10.1093/jrr/rru126 [PMC free article] [PubMed] [CrossRef[]
40. De Bari C, Dell’Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membraneArthritis Rheum. (2001) 44:1928–42. 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P [PubMed] [CrossRef[]
41. Paleolog E. Angiogenesis in rheumatoid arthritisArthritis Res Ther. (2002) 4:S81–90. 10.1186/ar575 [PMC free article] [PubMed] [CrossRef[]
42. McInnes I, Schett G. Cytokines in the pathogenesis of rheumatoid arthritisNat Rev Immunol. (2007) 7:429–42. 10.1038/nri2094 [PubMed] [CrossRef[]
43. McGonagle D, McDermott MF. A proposed classification of the immunological diseasesPLoS Med.(2006) 3:e297. 10.1371/journal.pmed.0030297 [PMC free article] [PubMed] [CrossRef[]
44. Cutolo M, Sulli A, Barone A, Seriolo B, Accardo S. Macrophages, synovial tissue and rheumatoid arthritisClin Exp Rheumatol. (1993) 11:331–9. [PubMed[]
45. Blom A, van Lent PL, Holthuysen AE, van der Kraan PM, Roth J, van Rooijen N, et al. . Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritisOsteoarthritis Cartil. (2004) 12:627–35. 10.1016/j.joca.2004.03.003 [PubMed] [CrossRef[]
46. Del Rey M, Faré R, Usategui A, Cañete JD, Bravo B, Galindo M, et al. . CD271(+) stromal cells expand in arthritic synovium and exhibit a proinflammatory phenotypeArthritis Res Ther. (2016) 18:66. 10.1186/s13075-016-0966-5 [PMC free article] [PubMed] [CrossRef[]
47. Tu J, Hong W, Zhang P, Wang X, Körner H, Wei W. Ontology and function of fibroblast-like and macrophage-like synoviocytes: how do they talk to each other and can they be targeted for rheumatoid arthritis therapy? Front Immunol. (2018) 9:1467. 10.3389/fimmu.2018.01467 [PMC free article][PubMed] [CrossRef[]
48. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and diseaseNat Rev Immunol.(2008) 8:726–36. 10.1038/nri2395 [PubMed] [CrossRef[]
49. Shi C. Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cellsImmunol Infect Dis. (2012) 136:133–8. 10.1111/j.1365-2567.2012.03567.x [PMC free article] [PubMed] [CrossRef[]
50. Markides H, Kehoe O, Morris RH, El Haj AJ. Whole body tracking of superparamagnetic iron oxide nanoparticle-labelled cells–a rheumatoid arthritis mouse modelStem Cell Res Ther. (2013) 4:126. 10.1186/scrt337 [PMC free article] [PubMed] [CrossRef[]
51. El-Jawhari J, El-Sherbiny YM, Jones EA, McGonagle D. Mesenchymal stem cells, autoimmunity and rheumatoid arthritisQJM. (2014) 107:505–14. 10.1093/qjmed/hcu033 [PMC free article] [PubMed] [CrossRef[]
52. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Mesenchymal stromal cell ‘licensing’: a multi-step processLeukemia (2011) 25:1408–14. 10.1038/leu.2011.108 [PubMed] [CrossRef[]
53. de Sousa E, Casado PL, Neto VM, Duarte MEL, Aguiar DP. Synovial fluid and synovial membrane mesenchymal stem cells: latest discoveries and therapeutic perspectivesStem Cell Res Ther. (2014) 5:112. 10.1186/scrt501 [PMC free article] [PubMed] [CrossRef[]
54. De Bari C. Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys? Arthritis Res Ther. (2015) 17:113 10.1186/s13075-015-0634-1 [PMC free article] [PubMed] [CrossRef[]
55. Vandenabeele F, De Bari C, Moreels M, Lambrichts I, Dell’Accio F, Lippens PL, et al. . Morphological and immunocytochemical characterization of cultured fibroblast-like cells derived from adult human synovial membraneArch. Histol. Cytol. (2003) 66:145–53. 10.1679/aohc.66.145 [PubMed] [CrossRef[]
56. Jorgensen C. Mesenchymal stem cells in arthritis: role of bone marrow microenvironmentArthritis Res Ther. (2010) 12:135–6. 10.1186/ar3105 [PMC free article] [PubMed] [CrossRef[]
57. Li R, Zhao SZ. Control and cross talk between angiogenesis and inflammation by mesenchymal stem cells for the treatment of ocular surface diseasesStem Cell Int. (2016) 2016:7961816. 10.1155/2016/2470351 [PMC free article] [PubMed] [CrossRef[]
58. Phinney D, Prockop DJ. Mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current viewsStem Cells. (2007) 25:2896–902. 10.1634/stemcells.2007-0637 [PubMed] [CrossRef[]
59. Tu X, Huang SX, Li WS, Song JX, Yang XL. Mesenchymal stem cells improve intestinal integrity during severe acute pancreatitisMol Med Rep. (2014) 10:1813–20. 10.3892/mmr.2014.2453 [PubMed] [CrossRef[]
60. Baharlou R, Ahmadi-Vasmehjani A, Faraji F, Atashzar MR, Khoubyari M, Ahi S, et al. Human adipose tissue-derived mesenchymal stem cells in rheumatoid arthritis: regulatory effects on peripheral blood mononuclear cell activationInt Immunopharmacol. (2017) 47:59–69. 10.1016/j.intimp.2017.03.016 [PubMed] [CrossRef[]
61. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responsesBlood. (2005) 105:1815–22. 10.1182/blood-2004-04-1559 [PubMed] [CrossRef[]
62. Kyurkchiev D, Bochev I, Ivanova-Todorova E, Mourdjeva M, Oreshkova T, Belemezova K, et al. . Secretion of immunoregulatory cytokines by mesenchymal stem cellsWorld J Stem Cells. (2014) 6:552–70. 10.4252/wjsc.v6.i5.552 [PMC free article] [PubMed] [CrossRef[]
63. Otto W, Wright NA. Mesenchymal stem cells: from experiment to clinicFibrogenesis Tissue Repair.(2011) 4:20. 10.1186/1755-1536-4-20 [PMC free article] [PubMed] [CrossRef[]
64. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. . Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 productionNat Med. (2009) 15:42–9. 10.1038/nm.1905 [PMC free article] [PubMed] [CrossRef[]
65. François M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiationMol Ther.(2012) 20:187–95. 10.1038/mt.2011.189 [PubMed] [CrossRef[]
66. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. . Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergyBlood. (2005) 106:1755–61. 10.1182/blood-2005-04-1496 [PubMed] [CrossRef[]
67. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interactionHaematol Lat. (2007) 92:881–8. 10.3324/haematol.11240 [PubMed] [CrossRef[]
68. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritisArthritis Rheum. (2007) 56:1175–86. 10.1002/art.22511 [PubMed] [CrossRef[]
69. Mayer-Wagner S, Passberger A, Sievers B, Aigner J, Summer B, Schiergens TS, et al. . Effects of low frequency electromagnetic fields on the chondrogenic differentiation of human mesenchymal stem cellsBioelectromagnetics. (2011) 32:283–90. 10.1002/bem.20633 [PubMed] [CrossRef[]
70. Ross C. Optimal Time of Efficacy for Using Bone Tissue Engineered Cell Therapies and Pulsed Electromagnetic Field [PEMF] for the Treatment of OsteoporosisCell Stem Cells Regen Med. (2017) 3:1–6. 10.16966/2472-6990.116 [CrossRef[]
71. Urnukhsaikhan E, Cho H, Mishig-Ochir T, Seo YK, Park JK. Pulsed electromagnetic fields promote survival and neuronal differentiation of human BM-MSCsLife Sci. (2016) 151:130–8. 10.1016/j.lfs.2016.02.066 [PubMed] [CrossRef[]
72. Viganò M, Sansone V, d’Agostino MC, Romeo P, Perucca Orfei C, de Girolamo L. Mesenchymal stem cells as therapeutic target of biophysical stimulation for the treatment of musculoskeletal disordersJ Orthop Surg Res. (2016) 11:163. 10.1186/s13018-016-0496-5 [PMC free article] [PubMed] [CrossRef[]
73. Fitzsimmons R, Gordon SL, Kronberg J, Ganey T, Pilla AA. A pulsing electric field (PEF) increases human chondrocyte proliferation through a transduction pathway involving nitric oxide signalingJ Orthop Res. (2008) 26:854–9. 10.1002/jor.20590 [PubMed] [CrossRef[]
74. Ross C, Harrison BS. An introduction to electromagnetic field therapy and immune function: a brief history and current statusJ Sci Appl Biosci. (2015) 3:17–28. []
75. Ross C, Harrison BS. Effect of pulsed electromagnetic field on inflammatory pathway markers in RAW 264.7 murine macrophages. J Inflamm Res. (2013) 6:45–51. 10.2147/JIR.S40269 [PMC free article] [PubMed] [CrossRef[]
76. Fini M, Pagaini S, Giavaresi G, De Mattei M, Ongaro N, Varani K, et al. . Functional tissue engineering in articular cartilage repair: is there a role for electromagnetic biophysical stimulation? Tissue Eng Part B Rev. (2013) 19:353–67. 10.1089/ten.teb.2012.0501 [PubMed] [CrossRef[]
77. Hong J, Kang KS, Yi HG, Kim SY, Cho DW. Electromagnetically controllable osteoclast activityBone. (2014) 62:99–107. 10.1016/j.bone.2014.02.005 [PubMed] [CrossRef[]
78. Chen C, Lin YS, Fu YC, Wang CK, Wu SC, Wang GJ, et al. Electromagnetic fields enhance chondrogenesis of human adipose-derived stem cells in a chondrogenic microenvironment in vitroBioelectromagnetics. (2013) 23:283–90. [PubMed[]
79. De Mattei M, Caruso A, Pezzetti F, Pellati A, Stabellini G, Sollazzo V, et al. . Effects of pulsed electromagnetic fields on human articular chondrocyte proliferationConnect Tissue Res. (2001) 42:269–79. 10.3109/03008200109016841 [PubMed] [CrossRef[]
80. Esposito M, Lucariello A, Costanzo C, Fiumarella A, Giannini A, Riccardi G, et al. . Differentiation of human umbilical cord-derived mesenchymal stem cells, WJ-MSCs, into chondrogenic cells in the presence of pulsed electromagnetic fieldsIn Vivo. (2013) 27:495–500. [PubMed[]
81. Parate D, Franco-Obregon A. Enhancement of mesenchymal stem cell chondrogenesis with short-term low intensity pulsed electromagnetic fieldNat Sci Rep. (2017) 7:9421 10.1038/s41598-017-09892-w [PMC free article] [PubMed] [CrossRef[]
82. Varani K, De Mattei M, Vincenzi F, Gessi S, Merighi S, Pellati A, et al. . Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fieldsOsteoarthritis Cartil. (2008) 16:292–304. 10.1016/j.joca.2007.07.004 [PubMed] [CrossRef[]
83. Yi Y. Role of inflammasomes in inflammatory autoimmune rheumatic diseasesKorean J Physiol Pharmacol. (2018) 22:1–15. 10.4196/kjpp.2018.22.1.1 [PMC free article] [PubMed] [CrossRef[]
84. Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F, et al. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long term rheumatoid arthritisJ Rheumatol. (2005) 32:2095–101. [PubMed[]
85. Lubberts E, van den Berg WB. Cytokines in the Pathogenesis of Rheumatoid Arthritis and Collagen-Induced ArthritisMol Immunol. (2000) 2000–13. [PubMed[]
86. Venkatesha S, Dudics S, Acharya B, Moudgil KD. Cytokine-modulating strategies and newer cytokine targets for arthritis therapyInt J Mol Sci. (2014) 16:887–906. 10.3390/ijms16010887 [PMC free article] [PubMed] [CrossRef[]
87. Martin-Martin L, Giovannangeli F, Bizzi E, Massafra U, Ballanti E, Cassol M, et al. . An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritisDrug Des Devel Ther. (2017) 11:985–94. 10.2147/DDDT.S118298 [PMC free article] [PubMed] [CrossRef[]
88. De Keyser F. Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection PerspectiveCurr Rheumatol Rev. (2011) 7:77–87. 10.2174/157339711794474620 [PMC free article][PubMed] [CrossRef[]
89. Strehblow C, Haberhauer G, Fasching P. Comparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapyWien Med Wochenschr. (2010) 160:225–9. 10.1007/s10354-010-0796-z [PubMed] [CrossRef[]
90. Metzger G. Biologics for RA. (2017) Available online at: https://www.webmd.com/rheumatoid-arthritis/features/ra-biologics-cost#1 (Accessed March 16, 2018).
91. Roman-Blas J, Jimenez SA. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritisOsteoarthritis Cartil. (2006) 14:839–48. 10.1016/j.joca.2006.04.008 [PubMed] [CrossRef[]
92. Lawrence T. The nuclear factor NF-?B pathway in inflammationCold Spring Harb Perspect Biol.(2009) 1:a001651. 10.1101/cshperspect.a001651 [PMC free article] [PubMed] [CrossRef[]
93. van Loo GBR. Negative regulation of NF-?B and its involvement in rheumatoid arthritisArthritis Res Ther. (2011) 13:221. 10.1186/ar3324 [PMC free article] [PubMed] [CrossRef[]
94. Vincenzi F, Targa M, Corciulo C, Gessi S, Merighi S, Setti S, et al. Pulsed electromagnetic fields increased the anti-inflammatory effect of A2A and A3 adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblasts. PLoS ONE. (2013) 8:e65561 10.1371/journal.pone.0065561 [PMC free article] [PubMed] [CrossRef[]
95. Simmonds R, Foxwell BM. Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammationRheumatology (Oxford). (2008) 47:584–90. 10.1093/rheumatology/kem298 [PubMed] [CrossRef[]
96. Ongaro A, Varani K, Masieri F, Pellati A, Massari L, Cadossi R, et al. . Electromagnetic fields (EMFs) and adenosine receptors modulate prostaglandin E(2) and cytokine release in human osteoarthritic synovial fibroblastsJ Cell Physiol. (2012) 227:2461–9. 10.1002/jcp.22981 [PubMed] [CrossRef[]
97. Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical applicationStem Cells Int. 2018:3057624. 10.1155/2018/3057624 [PMC free article] [PubMed] [CrossRef[]
98. Jasti A, Wetzel BJ, Aviles H, Vesper DN, Nindl G, Johnson MT. Effect of a wound healing electromagnetic field on inflammatory cytokine gene expression in ratsBiomed Sci Instrum. (2001) 37:209–14. [PubMed[]
99. Nelson F, Zvirbulis R, Pilla AA. Non-invasive electromagnetic field therapy produces rapid and substantial pain reduction in early knee osteoarthritis: a randomized double-blind pilot studyRheumatol Int. (2013) 33:2169–73. 10.1007/s00296-012-2366-8 [PubMed] [CrossRef[]
100. Rasouli J, Lekhraj R, White NM, Flamm ES, Pilla AA, Strauch B, et al. . Attenuation of interleukin-1beta by pulsed electromagnetic fields after traumatic brain injuryNeurosci Lett. (2012) 519:4–8. 10.1016/j.neulet.2012.03.089 [PubMed] [CrossRef[]
101. He Y, Liu DD, Fang YJ, Zhan XQ, Yao JJ, Mei YA. Exposure to extremely low-frequency electromagnetic fields modulates Na+ currents in rat cerebellar granule cells through increase of AA/PGE2 and EP receptor-mediated cAMP/PKA pathwayPLoS ONE. (2013) 8:e54376. 10.1371/journal.pone.0054376 [PMC free article] [PubMed] [CrossRef[]
102. Di Leva F, Domi T, Fedrizzi L, Lim D, Carafoli E. The plasma membrane Ca2+ ATPase of animal cells: structure, function and regulationArch Biochem Biophys. (2008) 476:65–74. 10.1016/j.abb.2008.02.026 [PubMed] [CrossRef[]
103. Segal N, Toda Y, Huston J, Saeki Y, Shimizu M, Fuchs H, et al. . Two configurations of static magnetic fields for treating rheumatoid arthritis of the knee: a double-blind clinical trialArch Phys Med Rehabil. (2001) 82:1453–60. 10.1053/apmr.2001.24309 [PubMed] [CrossRef[]
104. de Girolamo L, Viganò M, Galliera E, Stanco D, Setti S, Marazzi MG, et al. . In vitro functional response of human tendon cells to different dosages of low-frequency pulsed electromagnetic fieldKnee Surg Sports Traumatol Arthrosc. (2015) 23:3443–53. 10.1007/s00167-014-3143-x [PubMed] [CrossRef[]
105. Tang X, Alliston T, Goughlin D, Miller S, Zhang N, Waldorff EI, et al. . Dynamic imaging demonstrates that pulsed electromagnetic fields (PEMF) suppress IL-6 transcription in bovine nucleus pulposus cellsJ Orthop Res. 36:778–87. 10.1002/jor.23713 [PMC free article] [PubMed] [CrossRef[]
106. Elshabrawy H, Chen Z, Volin MV, Shalini Ravella S, Virupannavar S, Shahrara S. The pathogenic role of angiogenesis in rheumatoid arthritisAngiogenesis. (2015) 18:433–48. 10.1007/s10456-015-9477-2 [PMC free article] [PubMed] [CrossRef[]
107. Leblond A, Allanore Y, Avouac J. Targeting synovial neoangiogenesis in rheumatoid arthritisAutoimmun Rev. (2017) 16:594–601. 10.1016/j.autrev.2017.04.005 [PubMed] [CrossRef[]
108. Walsh D, Pearson CI. Angiogenesis in the pathogenesis of inflammatory joint and lung diseasesArthritis Res. (2001) 3:147–53. 10.1186/ar292 [PMC free article] [PubMed] [CrossRef[]
109. Taylor P, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritisCurr Opin Rheumatol.(2005) 17:293–8. 10.1097/01.bor.0000155361.83990.5b [PubMed] [CrossRef[]
110. Quiñonez-Flores C, González-Chávez SA, Pacheco-Tena C. Hypoxia and its implications in rheumatoid arthritisJ Biomed Sci. (2016) 23:62. 10.1186/s12929-016-0281-0 [PMC free article][PubMed] [CrossRef[]
111. Konisti S, Kiriakidis S, Paleolog EM. Hypoxia–a key regulator of angiogenesis and inflammation in rheumatoid arthritisNat Rev Rheumatol. (2012) 8:153–62. 10.1038/nrrheum.2011.205 [PubMed] [CrossRef[]
112. Sun X, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseasesHistol Histopathol. 22:1387–98. 10.14670/HH-22.1387 [PubMed] [CrossRef[]
113. Koch A, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol. (1994) 152:4149–56. [PubMed[]
114. Szekanecz Z, Koch AE. Mechanisms of Disease: angiogenesis in inflammatory diseasesNat Clin Pract Rheumatol. (2007) 3:635–43. 10.1038/ncprheum0647 [PubMed] [CrossRef[]
115. Szekanecz Z, Besenyei T, Szentpétery A, Koch AE. Angiogenesis and vasculogenesis in rheumatoid arthritisCurr Opin Rheumatol. (2010) 22:299–306. 10.1097/BOR.0b013e328337c95a [PubMed] [CrossRef[]
116. MacDonald IL, Li SC, Su CM, Wang YH, Tsai CH, Tang C. Implications of angiogenesis involvement in arthritisInt J Mol Sci. (2018) 19:E2012. 10.3390/ijms19072012 [PMC free article][PubMed] [CrossRef[]
117. Berse B, Hunt JA, Diegel RJ, Morganelli P, Yeo K, Brown F, et al. . Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblastsClin Exp Immunol. (1999) 115:176–82. 10.1046/j.1365-2249.1999.00775.x [PMC free article] [PubMed] [CrossRef[]
118. Stevens C, Blake DR, Merry P, Revell PA, Levick JR. A comparative study by morphometry of the microvasculature in normal and rheumatoid synoviumArthritis Rheum. (1991) 34:1508–13. 10.1002/art.1780341206 [PubMed] [CrossRef[]
119. Stevens C, Williams RB, Farrell AJ, Blake DR. Hypoxia and inflammatory synotitis: observations and speculationAnn Rheum Dis. (1991) 50:124–32. 10.1136/ard.50.2.124 [PMC free article] [PubMed] [CrossRef[]
120. Cho C, Cho ML, Min SY, Kim WU, Min DJ, Lee SS, et al. . CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factorJ Immunol. (2000) 164:5055–61. 10.4049/jimmunol.164.10.5055 [PubMed] [CrossRef[]
121. Cha H, Bae EK, Koh JH, Chai JY, Jeon CH, Ahn KS, et al. . Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytesJ Rheumatol. (2007) 34:16–9. [PubMed[]
122. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, et al. . Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesisMol Cell Biol. (1997) 17:4015–23. 10.1128/MCB.17.7.4015 [PMC free article][PubMed] [CrossRef[]
123. de Souza L, Malta TM, Kashima Haddad S, Covas DT. Mesenchymal stem cells and pericytes: to what extent are they related? Stem Cells Dev. (2016) 25:1843–52. 10.1089/scd.2016.0109 [PubMed] [CrossRef[]
124. Corselli M, Chen CW, Sun B, Yap S, Rubin JP, Péault B. The tunica adventitia of human arteries and veins as a source of mesenchymal stem cellsStem Cells Dev. (2012) 21:1299–308. 10.1089/scd.2011.0200 [PMC free article] [PubMed] [CrossRef[]
125. Fava R, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. . Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissueJ Exp Med. (1994) 180:341–6. 10.1084/jem.180.1.341 [PMC free article][PubMed] [CrossRef[]
126. Caplan A. All MSCs are pericytes? Cell Stem Cell. (2008) 3:229–30. 10.1016/j.stem.2008.08.008 [PubMed] [CrossRef[]
127. Feng J, Mantesso A, Sharpe PT. Perivascular cells as mesenchymal stem cellsExpert Opin Biol Ther. (2010) 10:1441–51. 10.1517/14712598.2010.517191 [PubMed] [CrossRef[]
128. Crisan M, Corselli M, Chen WC, Peault B. Perivascular cells for regenerative medicineJ Cell Mol Med. (2012) 16:2851–60. 10.1111/j.1582-4934.2012.01617.x [PMC free article] [PubMed] [CrossRef[]
129. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenanceNeuro Oncol.(2005) 7:452–64. 10.1215/S1152851705000232 [PMC free article] [PubMed] [CrossRef[]
130. Stapor P, Sweat RS, Dashti DC, Betancourt AM, Murfee WL. Pericyte dynamics during angiogenesis: new insights from new identitiesJ Vasc Res. (2014) 51:163–74. 10.1159/000362276 [PMC free article] [PubMed] [CrossRef[]
131. Maziarz A, Kocan B, Bester M, Budzik S, Cholewa M, Ochiya T, et al. . How electromagnetic fields can influence adult stem cells: positive and negative impactsStem Cell Res Ther. (2016) 7:54. 10.1186/s13287-016-0312-5 [PMC free article] [PubMed] [CrossRef[]
132. Gerhardt H, Betsholtz C. Endothelial-pericyte interaction in angiogensisCell Tissue Res. (2003) 314:15–23. 10.1007/s00441-003-0745-x [PubMed] [CrossRef[]
133. Peppiatt C, Howarth C, Mobbs P, Attwell D. Bidirectional control of CNS capillary diameter by pericytesNature. (2006) 443:700–4. 10.1038/nature05193 [PMC free article] [PubMed] [CrossRef[]
134. Abarbanell A, Coffey AC, Fehrenbacher JW, Beckman DJ, Herrmann JL, Weil B, et al. Directing migration of endothelial progenitor cells with applied DC electric fieldsStem Cell Res. (2012) 8:38–48. 10.1016/j.scr.2011.08.001 [PMC free article] [PubMed] [CrossRef[]
135. Ma F, Li W, Li X, Tran BH, Suguro R, Guan R, et al. . Novel protective effects of pulsed electromagnetic field ischemia/reperfusion injury ratsBiosci Rep. (2016) 36:e00420. 10.1042/BSR20160082 [PMC free article] [PubMed] [CrossRef[]
136. Murray I, West CC, Hardy WR, James AW, Park TS, Nguyen A, et al. . Natural history of mesenchymal stem cells, from vessel walls to culture vesselsCell Mol Life Sci. (2014) 71:1353–74. 10.1007/s00018-013-1462-6 [PubMed] [CrossRef[]
137. Fan W, Qian F, Ma Q, Zhang P, Chen T, Chen C, et al. . 50 Hz electromagnetic field exposure promotes proliferation and cytokine production of bone marrow mesenchymal stem cellsInt J Clin Exp Med. (2015) 8:7394–404. [PMC free article] [PubMed[]
138. Hong K, Cho ML, Min SY, Shin YJ, Yoo SA, Choi JJ, et al. . Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblastsClin Exp Immunol. (2007) 147:573–9. 10.1111/j.1365-2249.2006.03295.x [PMC free article] [PubMed] [CrossRef[]
139. Shin T, Kim HS, Kang TW, Lee BC, Lee HY, Kim YJ, et al. . Human umbilical cord blood-stem cells direct macrophage polarization and block inflammasome activation to alleviate rheumatoid arthritisCell Death Dis. (2016) 7:e2524. 10.1038/cddis.2016.442 [PMC free article] [PubMed] [CrossRef[]
140. McKay J, Prato FS, Thomas AW. The effects of magentic field exposure on blood flow and blood vessels in the microvasculaturebioelectromagnetics. (2007) 28:81–98. [PubMed[]
141. Okana H, Tomita N, Ikada Y. Spatial gradient effects of 120 mT static magnetic field on endothelial tubular formation in vitroBioelectromagnetics. (2008) 29:233–6. 10.1002/bem.20376 [PubMed] [CrossRef[]
142. Williams C, Markov MS, Hardman WE, Cameron IL. Therapeutic electromagnetic field effects on angiogenesis and tumor growthAnticancer Res. (2001) 21:3887–91. [PubMed[]
143. Baker R. Human magnetoreception for navigation: electromagnetic fields and neurobehavioral functionProg Clin Biol Res. (1988) 257:63–80. [PubMed[]
144. Cook C, Thomas AW, Prato FS. Human electrophysiological and cognitive effects of exposure to ELF magnetic and ELF modulated RF and microwave fields: a review of recent studiesBioelectromagnetics. (2002) 23:144–57. 10.1002/bem.107 [PubMed] [CrossRef[]
145. Sartucci F, Bonfiglio L, Del Seppia C, Luschi P, Ghione S, Murri L, et al. . Changes in pain perception and pain-related somatosensory evoked potentials in humans produced by exposure to oscillating magnetic fieldsBrain Res. (1997) 769:362–6. 10.1016/S0006-8993(97)00755-5 [PubMed] [CrossRef[]
146. Shupak N, Prato FS, Thomas AW. Human exposure to a specific pulsed magnetic field: Effects of thermal sensory and pain thresholdNeurosci Lett. (2004) 363:157–62. 10.1016/j.neulet.2004.03.069 [PubMed] [CrossRef[]
147. Li R, Huang JJ, Shi YQ, Hu A, Lu ZY, Weng L, et al. . Pulsed electromagnetic field improves postnatal neovascularization in response to hindlimb ischemiaAm J Transl Res. (2015) 7:430–44. 10.1136/heartjnl-2014-307109.20 [PMC free article] [PubMed] [CrossRef[]
148. Wang Z, Yang P, Xu H, Qian A, Hu L, Shang P. Inhibitory effects of a gradient static magnetic field on normal angiogenesisBioelectromagnetics. (2009) 30:446–53. 10.1002/bem.20501 [PubMed] [CrossRef[]
149. Ross C, Teli T, Harrison B. Electromagnetic field devices and their effect on nociception and peripheral inflammatory pain mechanismsAltern Ther Health Med. (2016) 22:34–47. [PubMed[]
150. Leoci R, Aiudi G, Silvestre F, Lissner E, Lacalandra GM. Effect of pulsed electromagnetic field therapy on prostate volume and vascularity in the treatment of benign prostatic hyperplasia: a pilot study in a canine modelProstate Cancer Prostatic Dis. (2014) 74:1132–41. 10.1002/pros.22829 [PMC free article] [PubMed] [CrossRef[]
151. Tsong T, Liu DS, Chauvin F, Astumian RD. Resonance electroconformational coupling: a proposed mechanism for energy and signal transductions by membrane proteinsBiosci Rep. (1989) 9:13–26. 10.1007/BF01117508 [PubMed] [CrossRef[]
152. Tsong T. Electrical modulation of membrane proteins: enforced conformational oscillations and biologial energy and signal transductionAnnu Rev Biophys Biophys Chem. (1990) 19:83–106. 10.1146/annurev.bb.19.060190.000503 [PubMed] [CrossRef[]
153. Tsong T. Molecular recognition and processing of periodic signals in cells: study of activation of membrane ATPases by alternating electric fieldsBiochim Biophys Acta. (1992) 1113:53–70. 10.1016/0304-4157(92)90034-8 [PubMed] [CrossRef[]
154. Liboff A. Geomagnetic cyclotron resonance in living cellsJ Biol Phys. (1985) 13:99–104. 10.1007/BF01878387 [CrossRef[]
155. De Ninno A, Pregnolato M. Electromagnetic homeostasis and the role of low-amplitude electromagnetic fields on life organizationElectromagn Biol Med. (2017) 36:115–22. 10.1080/15368378.2016.1194293 [PubMed] [CrossRef[]
156. Buckner C, Buckner AL, Koren SA, Persinger MA, Lafrenie RM. Inhibition of cancer cell growth by exposure to a specific time-varying electromagnetic field involves T-type calcium channelsPLoS ONE.(2015) 10:e0124136. 10.1371/journal.pone.0124136 [PMC free article] [PubMed] [CrossRef[]
157. Ikehara T, Yamaguchi H, Miyamoto H. Effects of electromagnetic fields on membrane ion transport of cultured cellsJ Med Invest. (1998) 45:47–56. [PubMed[]
158. Ross C, Pettenati MJ, Procita J, Cathey L, George SK, Almeida-Porada G. Evaluation of cytotoxic and genotoxic effects of extremely low-frequency electromagnetic field on mesenchymal stromal cellsGlob Adv Health Med. (2018) 7:2164956118777472. 10.1177/2164956118777472 [PMC free article][PubMed] [CrossRef[]
159. Rubik B, Muehsam D, Hammerschlag R, Jain S. Biofield science and healing: history, terminology, and conceptsGlob Adv Health Med. (2015) 4:8–14. 10.7453/gahmj.2015.038.suppl [PMC free article][PubMed] [CrossRef[]
160. Adravanti P, Nicoletti S, Setti S, Ampollini A, de Girolamo L. Effect of pulsed electromagnetic field therapy in patients undergoing total knee arthroplasty: a randomised controlled trialInt Orthop. (2014) 38:397–403. 10.1007/s00264-013-2216-7 [PMC free article] [PubMed] [CrossRef[]
161. Meyers B. PEMF: The 5th Element of Health. In: Meyers Balboa Presse Medicale Bloomington, IN: Balboa Press/Hay House; (2013). p. 93. []

Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

 

Rheumatol Int. 2010 Mar;30(5):571-86. Epub 2009 Oct 30.

Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities.

Efthimiou P, Kukar M.

Rheumatology Division, Lincoln Medical and Mental Health Center, Weill Cornell Medical College, 234 E. 149th Street, New York, NY 10451, USA. petrosefthimiou@gmail.com

Abstract

Complementary and alternative medicine (CAM) has become popular in patients with rheumatoid arthritis (RA) worldwide. The objective of this study is to systematically review the proposed mechanisms of action and currently available evidence supporting the efficacy of CAM modalities in relieving signs and symptoms of RA. The prevalence of CAM usage by RA patients is anywhere from 28% to 90%. Many published studies on CAM are based on animal models of RA and there is often insufficient evidence for the efficacy of CAM modalities in RA. The existing evidence suggests that some of the CAM modalities, such as acupuncture, herbal medicines, dietary omega-3 fatty acids, vitamins, and pulsed electromagnetic field show promising efficacy in reducing pain. While the use of CAM modalities for the treatment of RA continues to increase, rigorous clinical trials examining their efficacy are necessary to validate or refute the clinical claims made for CAM therapies.

Indian J Exp Biol.  2009 Dec;47(12):939-48.

Low frequency pulsed electromagnetic field–a viable alternative therapy for arthritis.

Ganesan K, Gengadharan AC, Balachandran C, Manohar BM, Puvanakrishnan R.

Source

Department of Biotechnology, Central Leather Research Institute, Adyar, Chennai 600 020, India.

Abstract

Arthritis refers to more than 100 disorders of the musculoskeletal system. The existing pharmacological interventions for arthritis offer only symptomatic relief and they are not definitive and curative. Magnetic healing has been known from antiquity and it is evolved to the present times with the advent of electromagnetism. The original basis for the trial of this form of therapy is the interaction between the biological systems with the natural magnetic fields. Optimization of the physical window comprising the electromagnetic field generator and signal properties (frequency, intensity, duration, waveform) with the biological window, inclusive of the experimental model, age and stimulus has helped in achieving consistent beneficial results. Low frequency pulsed electromagnetic field (PEMF) can provide noninvasive, safe and easy to apply method to treat pain, inflammation and dysfunctions associated with rheumatoid arthritis (RA) and osteoarthritis (OA) and PEMF has a long term record of safety. This review focusses on the therapeutic application of PEMF in the treatment of these forms of arthritis. The analysis of various studies (animal models of arthritis, cell culture systems and clinical trials) reporting the use of PEMF for arthritis cure has conclusively shown that PEMF not only alleviates the pain in the arthritis condition but it also affords chondroprotection, exerts antiinflammatory action and helps in bone remodeling and this could be developed as a viable alternative for arthritis therapy.

Life Sci. 2007 Jun 6;80(26):2403-10. Epub 2007 May 1.

Low frequency and low intensity pulsed electromagnetic field exerts its antiinflammatory effect through restoration of plasma membrane calcium ATPase activity.

Selvam R, Ganesan K, Narayana Raju KV, Gangadharan AC, Manohar BM, Puvanakrishnan R.

Department of Pharmacology and Toxicology, Madras Veterinary College, Vepery, Chennai, India.

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disorder affecting 1% of the population worldwide. Pulsed electromagnetic field (PEMF) has a number of well-documented physiological effects on cells and tissues including antiinflammatory effect. This study aims to explore the antiinflammatory effect of PEMF and its possible mechanism of action in amelioration of adjuvant induced arthritis (AIA). Arthritis was induced by a single intradermal injection of heat killed Mycobacterium tuberculosis at a concentration of 500 microg in 0.1 ml of paraffin oil into the right hind paw of rats. The arthritic animals showed a biphasic response regarding changes in the paw edema volume. During the chronic phase of the disease, arthritic animals showed an elevated level of lipid peroxides and depletion of antioxidant enzymes with significant radiological and histological changes. Besides, plasma membrane Ca(2+) ATPase (PMCA) activity was inhibited while intracellular Ca(2+) level as well as prostaglandin E(2) levels was noticed to be elevated in blood lymphocytes of arthritic rats. Exposure of arthritic rats to PEMF at 5 Hzx4 microT x 90 min, produced significant antiexudative effect resulting in the restoration of the altered parameters. The antiinflammatory effect could be partially mediated through the stabilizing action of PEMF on membranes as reflected by the restoration of PMCA and intracellular Ca(2+) levels in blood lymphocytes subsequently inhibiting PGE(2) biosynthesis. The results of this study indicated that PEMF could be developed as a potential therapy for RA in human beings.

Pain Res Manag. 2006 Summer;11(2):85-90.

Exposure to a specific pulsed low-frequency magnetic field: a double-blind placebo-controlled study of effects on pain ratings in rheumatoid arthritis and fibromyalgia patients.

Shupak NM, McKay JC, Nielson WR, Rollman GB, Prato FS, Thomas AW.

Lawson Health Research Institute, St. Joseph’s Health Care, London, Ontario N6A 4V2.

Abstract

BACKGROUND: Specific pulsed electromagnetic fields (PEMFs) have been shown to induce analgesia (antinociception) in snails, rodents and healthy human volunteers.

OBJECTIVE: The effect of specific PEMF exposure on pain and anxiety ratings was investigated in two patient populations.

DESIGN: A double-blind, randomized, placebo-controlled parallel design was used.

METHOD: The present study investigated the effects of an acute 30 min magnetic field exposure (less than or equal to 400 microTpk; less than 3 kHz) on pain (McGill Pain Questionnaire [MPQ], visual analogue scale [VAS]) and anxiety (VAS) ratings in female rheumatoid arthritis (RA) (n=13; mean age 52 years) and fibromyalgia (FM) patients (n=18; mean age 51 years) who received either the PEMF or sham exposure treatment.

RESULTS: A repeated measures analysis revealed a significant pre-post-testing by condition interaction for the MPQ Pain Rating Index total for the RA patients, F(1,11)=5.09, P<0.05, estimate of effect size = 0.32, power = 0.54. A significant pre-post-effect for the same variable was present for the FM patients, F(1,15)=16.2, P<0.01, estimate of effect size = 0.52, power =0.96. Similar findings were found for MPQ subcomponents and the VAS (pain). There was no significant reduction in VAS anxiety ratings pre- to post-exposure for either the RA or FM patients.

CONCLUSION: These findings provide some initial support for the use of PEMF exposure in reducing pain in chronic pain populations and warrants continued investigation into the use of PEMF exposure for short-term pain relief.

Acupunct Electrother Res. 2003;28(1-2):11-8.

Treatment of rheumatoid arthritis with electromagnetic millimeter waves applied to acupuncture points–a randomized double blind clinical study.

Usichenko TI, Ivashkivsky OI, Gizhko VV.

Anesthesiology & Intensive Care Medicine Department, University of Greifswald, Germany. taras@uni-greifswald.de

Abstract

The aim of the study was to evaluate the efficacy and safety of electromagnetic millimeter waves (MW) applied to acupuncture points in patients with rheumatoid arthritis (RA). Twelve patients with RA were exposed to MW with power 2.5 mW and band frequency 54-64 GHz. MW were applied to the acupuncture points of the affected joints in a double blind manner. At least 2 and maximum 4 points were consecutively exposed to MW during one session. Total exposure time consisted of 40 minutes. According to the study design, group I received only real millimeter wave therapy (MWT) sessions, group II only sham sessions. Group III was exposed to MW in a random cross-over manner. Pain intensity, joint stiffness and laboratory parameters were recorded before, during and immediately after the treatment. The study was discontinued because of beneficial therapeutic effects of MWT. Patients from group I (n=4) reported significant pain relief and reduced joint stiffness during and after the course of therapy. Patients from group II (n=4) revealed no improvement during the study. Patients from group III reported the changes of pain and joint stiffness only after real MW sessions. After further large-scale clinical investigations MWT may become a non-invasive adjunct in therapy of patients with RA.

Neurosci Lett. 2001 Aug 17;309(1):17-20.

A comparison of rheumatoid arthritis and fibromyalgia patients and healthy controls exposed to a pulsed (200 microT) magnetic field: effects on normal standing balance.

Thomas AW, White KP, Drost DJ, Cook CM, Prato FS.

The Lawson Health Research Institute, Department of Nuclear Medicine & MR, St. Joseph’s Health Care, 268 Grosvenor Street, London, N6A 4V2, Ontario, Canada. athomas@lri.sjhc.london.on.ca

Specific weak time varying pulsed magnetic fields (MF) have been shown to alter animal and human behaviors, including pain perception and postural sway. Here we demonstrate an objective assessment of exposure to pulsed MF’s on Rheumatoid Arthritis (RA) and Fibromyalgia (FM) patients and healthy controls using standing balance. 15 RA and 15 FM patients were recruited from a university hospital outpatient Rheumatology Clinic and 15 healthy controls from university students and personnel. Each subject stood on the center of a 3-D forceplate to record postural sway within three square orthogonal coil pairs (2 m, 1.75 m, 1.5 m) which generated a spatially uniform MF centered at head level. Four 2-min exposure conditions (eyes open/eyes closed, sham/MF) were applied in a random order. With eyes open and during sham exposure, FM patients and controls appeared to have similar standing balance, with RA patients worse. With eyes closed, postural sway worsened for all three groups, but more for RA and FM patients than controls. The Romberg Quotient (eyes closed/eyes open) was highest among FM patients. Mixed design analysis of variance on the center of pressure (COP) movements showed a significant interaction of eyes open/closed and sham/MF conditions [F=8.78(1,42), P<0.006]. Romberg Quotients of COP movements improved significantly with MF exposure [F=9.5(1,42), P<0.005] and COP path length showed an interaction approaching significance with clinical diagnosis [F=3.2(1,28), P<0.09]. Therefore RA and FM patients, and healthy controls, have significantly different postural sway in response to a specific pulsed MF.

Arch Phys Med Rehabil. 2001 Oct;82(10):1453-60.

Two configurations of static magnetic fields for treating rheumatoid arthritis of the knee: a double-blind clinical trial.

Segal NA, Toda Y, Huston J, Saeki Y, Shimizu M, Fuchs H, Shimaoka Y, Holcomb R, McLean MJ.

Vanderbilt University Medical School, Nashville, TN 37232, USA.

Abstract

OBJECTIVE: To assess the efficacy of a nonpharmacologic, noninvasive static magnetic device as adjunctive therapy for knee pain in patients with rheumatoid arthritis (RA).

DESIGN: Randomized, double-blind, controlled, multisite clinical trial.

SETTING: An American and a Japanese academic medical center as well as 4 community rheumatology and orthopedics practices.

PATIENTS: Cohort of 64 patients over age 18 years with rheumatoid arthritis and persistent knee pain, rated greater than 40/100mm, despite appropriate use of medications.

INTERVENTION: Four blinded MagnaBloc (with 4 steep field gradients) or control devices (with 1 steep field gradient) were taped to a knee of each subject for 1 week.

MAIN OUTCOME MEASURES: The American College of Rheumatology recommended core set of disease activity measures for RA clinical trials and subjects’ assessment of treatment outcome.

RESULTS: Subjects randomly assigned to the MagnaBloc (n = 38) and control treatment groups (n = 26) reported baseline pain levels of 63/100mm and 61/100mm, respectively. A greater reduction in reported pain in the MagnaBloc group was sustained through the 1-week follow-up (40.4% vs 25.9%) and corroborated by twice daily pain diary results (p < .0001 for each vs baseline). However, comparison between the 2 groups demonstrated a statistically insignificant difference (p < .23). Subjects in the MagnaBloc group reported an average decrease in their global assessment of disease activity of 33% over 1 week, as compared with a 2% decline in the control group (p < .01). After 1 week, 68% of the MagnaBloc treatment group reported feeling better or much better, compared with 27% of the control group, and 29% and 65%, respectively, reported feeling the same as before treatment (p < .01).

CONCLUSIONS: Both devices demonstrated statistically significant pain reduction in comparison to baseline, with concordance across multiple indices. However, a significant difference was not observed between the 2 treatment groups (p < .23). In future studies, the MagnaBloc treatment should be compared with a nonmagnetic placebo treatment to characterize further its therapeutic potential for treating RA. This study did elucidate methods for conducting clinical trials with magnetic devices.

J Indian Med Assoc. 1998 Sep;96(9):272-5.

A study of the effects of pulsed electromagnetic field therapy with respect to serological grouping in rheumatoid arthritis.

Ganguly KS, Sarkar AK, Datta AK, Rakshit A.

National Institute for the Orthopaedically Handicapped (NIOH), Calcutta.

The positive role of pulsed electromagnetic field (PEMF) therapy in rheumatoid arthritis (RA) is known. The differential role of serological status of patients in RA is also well known. This paper presents a study of the differential effects of PEMF therapy on the two serological groups of patients. The responses of the seropositive patients are found to be more subdued. Varying effects of the therapy in alleviating the different symptomatologies indicate that the rheumatoid factor (RF) is more resistant to PEMF.

Eur J Clin Chem Clin Biochem. 1994 Apr;32(4):319-26.

Influence of electromagnetic fields on the enzyme activity of rheumatoid synovial fluid cells in vitro.

Mohamed-Ali H, Kolkenbrock H, Ulbrich N, Sorensen H, Kramer KD, Merker HJ.

Institut fur Anatomie, Freie Universitat Berlin, Germany.

Since positive clinical effects have been observed in the treatment of rheumatoid arthritis with electromagnetic fields of weak strength and low frequency range (magnetic field strength: 70 microT; frequency: 1.36-14.44 Hz), an attempt was made to analyse the effects of these electromagnetic fields on enzyme activity in monolayer cultures of rheumatoid synovial fluid cells after single irradiation of the cultures for 24 hours. We only investigated the matrix metalloproteinases (collagenase, gelatinase, proteinase 24.11 and aminopeptidases). It was found that electromagnetic fields of such a weak strength and low frequency range do not generally have a uniform effect on the activity of the different proteinases in vitro. While aminopeptidases do not show any great changes in activity, the peptidases hydrolysing N(2,4)-dinitrophenyl-peptide exhibit a distinct increase in activity in the late phase in culture medium without fetal calf serum. In the presence of fetal calf serum this effect is not observed and enzyme activity is diminished. Our experiments do not show whether such a phase-bound increase in the activity of proteinases in vitro is only one finding in a much broader range of effects of electromagnetic fields, or whether it is a specific effect of weak pulsed magnetic fields of 285 +/- 33 nT on enzyme activity after single irradiation. This question requires further elucidation.

Vopr Kurortol Fizioter Lech Fiz Kult. 1992 Jul-Aug;(4):9-13.

The combined action of an ultrahigh-frequency electrical field bitemporally and decimeter waves on the thymus area in the combined therapy of rheumatoid arthritis patients.

[Article in Russian]

Sidorov VD, Grigor’eva VD, Pershin SB, Bobkova AS, Korovkina EG.

Abstract

The thymus of rheumatoid arthritis (RA) patients was exposed to combined action of bitemporal UHF electric field and decimeter waves to study immunomodulating effect of the combination. Biochemical, immunological and endocrinological findings during the patients follow-up gave evidence for conclusion on activation of the hypothalamic-hypophyseal-thymic axis. A response was achieved in RA seronegative variant with concomitant synovitis. This may be due to genetic factors.